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Plant secondary metabolites are chemically diverse compounds, some of which have been largely exploited as 
pharmaceuticals, food additives and flavours. Flavonoids and other phenolic compounds constitute one of the 
main classes of secondary metabolites.1,2 As one of the most abundant form of flavonoids, quercetin (3,3’, 4’, 
5,7-pentahydroxyflavone) has been receiving much attention owing to its potential antioxidant, anti-allergic, anti-
inflammatory, anti-cancer, anti-diabetic, anti-microbial and cardio-protective properties.1
Keloids are exuberant overgrowths of scar with excessive fibroblast proliferation and matrix deposition, which 
has the ability to spread beyond the original boundary of the wound.3 Despite existence of a wide array of therapies 
available for keloids, no treatment is yet considered completely effective. Corticosteroids, surgical excision, silicone 
sheeting, cryosurgery, radiotherapy, laser therapy and photodynamic therapy have been extensively applied to treat 
keloids.4 Other promising approaches such as mesenchymal stem cell therapy, fat grafting, electrical stimulation, 
and deployment of RNA interference seem to be beneficial for the treatment of keloids.5 Over the past years, 
studies found compelling evidence that indicate the advantageous properties of quercetin as a potential candidate 
for adjuvant therapy of keloids.3,4
According to Si et al.’s recent study, keloid fibroblasts treated with quercetin showed augmented sensitisation 
to radiation compared to untreated cells.3 The main mechanism underlying the suppression of radio-resistance 
by quercetin is down-regulation of hypoxia-inducible factor 1, a prognostic factor used in clinical practice 
after radiation therapy, through the phosphoinositide 3-kinase/Akt pathway.3 An in vitro study by Mathangi 
Ramakrishnan et al. revealed a dose-dependent action of quercetin and vitamin D3 on isolated keloid fibroblasts.4 
In this context, both agents alone were capable of reducing either collagen I synthesis or B-cell lymphoma 2 gene 
expression and increasing caspase-3 levels in fibroblast cells, resulting in higher number of apoptotic fibroblasts.4 
Cho et al. found that quercetin and onion extract diminished the proliferation rate of fibroblasts in a concentrate-
dependent manner by up-regulation of matrix metalloproteinase-1 expression levels in vitro and in vivo.2 However, 
contrary to expectations, expression levels of type I collagen were not markedly changed. Khonkarn et al. attempted 
to develop a quercetin-incorporated microemulsion-based gel formulation for topical delivery against keloids and 
concluded that the developed gel may be a promising vehicle for topical drug delivery.6
Doersch and Newell-Rogers found that quercetin diminishes fibrosis at wound sites in quercetin-treated 
mice by altering cell interactions with the extracellular matrix (ECM) through increasing αV- and decreasing 
β1-integrin expression levels.1 This would enhance cell migration with less ECM requirement to facilitate wound 
closure. Gopalakrishnan et al. showed beneficial properties of 0.1% quercetin ointment in accelerating cutaneous 
wound healing in rats by increasing the expression levels of vascular endothelial growth factor, transforming growth 
factor-β1 and interleukin-10 as well as reducing tumour necrosis factor-α levels in rats.7 In addition, quercetin-
treated rats exhibited less inflammatory cells, more regular collagen deposition and better re-epithelialisation 
compared to the control group.7
Multiple approaches can be propounded to improve therapeutic efficacy of quercetin for ideal skin delivery. 
The conjugation of quercetin with nanoparticles or fatty acids and designing quercetin-based hydrogels are 
novel strategies for combating keloids. Furthermore, the use of quercetin as an adjuvant therapy with other anti-
keloid treatments may result in lower keloid recurrence rates. In patients with keloids and hypertrophic scars, 
onion extract gel which is a rich source of quercetin, has been shown to be beneficial when combined with other 
therapeutic strategies such as silicone gel sheet and corticosteroids.8,9 In terms of sensitiveness, pain, itching and 
elevation, intralesional triamcinolone acetonide plus onion extract gel was superior to triamcinolone acetonide 
alone.8 Hosnuter et al.’s comparative prospective study combined onion extract gel and silicone gel sheet, which 
significantly reduced scar height; the combination was found to be more effective than onion extract gel alone.9 
Hamideh Moravvej, Mojtaba Memariani and Hamed Memariani
Letter to the Editor | e373
Quercetin can be formulated in different dermatological preparations such as micro-emulsion gels, liposomes 
and a nanostructured lipid carrier. These formulations can be used topically for both prevention and treatment of 
keloid scars. Overall, the propitious role of quercetin as an immunomodulatory, anti-fibrotic agent will hopefully 
increase the treatment options available for patients who are afflicted with keloids, hypertrophic scars and wounds.
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